Cellectis (NASDAQ:CLLS) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Cellectis (NASDAQ:CLLS) in a report published on Wednesday. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, Barclays lowered their target price on shares of Cellectis from $7.00 to $5.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 5th.

Cellectis Price Performance

NASDAQ CLLS opened at $1.98 on Wednesday. The firm has a market capitalization of $110.06 million, a price-to-earnings ratio of -1.52 and a beta of 3.10. The company has a 50 day simple moving average of $2.02 and a 200-day simple moving average of $2.25. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.78 and a quick ratio of 1.78. Cellectis has a 52-week low of $1.70 and a 52-week high of $3.77.

Cellectis (NASDAQ:CLLS) last announced its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03). The firm had revenue of $18.05 million during the quarter, compared to the consensus estimate of $5.00 million. Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. During the same quarter in the prior year, the business posted ($0.31) EPS. Equities research analysts predict that Cellectis will post -0.46 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cellectis

A number of large investors have recently bought and sold shares of CLLS. Long Focus Capital Management LLC lifted its position in shares of Cellectis by 2.9% during the second quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock worth $8,634,000 after purchasing an additional 130,000 shares in the last quarter. Principal Financial Group Inc. grew its stake in shares of Cellectis by 2.9% during the second quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock valued at $817,000 after purchasing an additional 12,467 shares during the last quarter. First Affirmative Financial Network bought a new stake in shares of Cellectis during the third quarter valued at approximately $45,000. Finally, XTX Topco Ltd bought a new stake in shares of Cellectis during the second quarter valued at approximately $29,000. 63.90% of the stock is currently owned by institutional investors.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.